- Home
- WDI vs MRVI Comparison
WDI vs MRVI Comparison
Compare WDI & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- MRVI
- Stock Information
- Founded
- WDI 2021
- MRVI 2020
- Country
- WDI United States
- MRVI United States
- Employees
- WDI N/A
- MRVI N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- MRVI Health Care
- Exchange
- WDI Nasdaq
- MRVI Nasdaq
- Market Cap
- WDI 786.7M
- MRVI 809.2M
- IPO Year
- WDI N/A
- MRVI 2020
- Fundamental
- Price
- WDI $14.43
- MRVI $5.37
- Analyst Decision
- WDI
- MRVI Buy
- Analyst Count
- WDI 0
- MRVI 10
- Target Price
- WDI N/A
- MRVI $10.28
- AVG Volume (30 Days)
- WDI 192.6K
- MRVI 1.7M
- Earning Date
- WDI 01-01-0001
- MRVI 02-20-2025
- Dividend Yield
- WDI 11.80%
- MRVI N/A
- EPS Growth
- WDI N/A
- MRVI N/A
- EPS
- WDI 1.12
- MRVI N/A
- Revenue
- WDI N/A
- MRVI $276,920,000.00
- Revenue This Year
- WDI N/A
- MRVI N/A
- Revenue Next Year
- WDI N/A
- MRVI $3.41
- P/E Ratio
- WDI $12.82
- MRVI N/A
- Revenue Growth
- WDI N/A
- MRVI N/A
- 52 Week Low
- WDI $12.16
- MRVI $4.28
- 52 Week High
- WDI $14.69
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- WDI 32.98
- MRVI 43.61
- Support Level
- WDI $14.84
- MRVI $5.30
- Resistance Level
- WDI $15.03
- MRVI $6.01
- Average True Range (ATR)
- WDI 0.19
- MRVI 0.35
- MACD
- WDI -0.06
- MRVI 0.06
- Stochastic Oscillator
- WDI 19.35
- MRVI 31.37
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.